Ebrahimpour Sholeh, Kargar Mona, Balvardi Mohadeseh, Tabatabaei-Malazy Ozra, Asadi Pardis, Mohammadi Mehdi
Department of Clinical Pharmacy, School of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran.
Pharmaceutical Care Department, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj, Iran.
Asian J Urol. 2025 Apr;12(2):189-203. doi: 10.1016/j.ajur.2024.05.003. Epub 2024 Sep 19.
Medical expulsive therapy (MET) is a suitable option for facilitating stone expulsion in patients with distal ureteral stones. This meta-analysis was conducted to compare efficacy and safety of monotherapy and combination therapy with tamsulosin, silodosin, and tadalafil on stone expulsion rate (SER) and stone expulsion time (SET), as well as their comparative safety, numbers of colic pain episodes, and need for analgesics.
Randomized controlled trials were retrieved by searching PubMed, Scopus, and Web of Science up to November 27, 2023. Hand-searching was also conducted in Google Scholar to find additional records. Papers in English that compared the safety and efficacy of at least two of the above agents in adults with distal ureteral stones ≤10 mm were included.
In total, 27 studies were identified (six studies through database searches and 21 through checking reference lists and hand-searching in Google Scholar). More than half of them (=15, 56%) were conducted in India. The SER significantly improved with silodosin compared with tamsulosin (odds ratio [OR] 2.24, <0.001), whereas the difference in SET was non-significant. Tadalafil achieved a significantly higher SER compared with tamsulosin (OR 1.42, =0.042) without any difference in SET. Subgroup analysis of 5- and 10-mg doses of tadalafil showed no significant difference in SER or SET. We found no significant difference in need for analgesics (mean difference [MD -53.73, =0.2) or the mean number of colic episodes (MD -0.42, =0.060) between tadalafil and tamsulosin. SER or SET was not significantly different between silodosin and tadalafil. Tadalafil plus tamsulosin led to a significantly higher SER (OR 1.87, <0.001) and SET (MD -2.99, =0.002) compared with tamsulosin, without any significant difference in adverse effects.
Compared with tamsulosin, SER significantly improved with silodosin, tadalafil, and the combination of tadalafil plus tamsulosin. Meanwhile, the difference in SET was only significant between tadalafil plus tamsulosin versus tamsulosin. It appears that tadalafil and silodosin have similar efficacy in SET and SER. All medical expulsive therapies had comparable safety.
药物排石疗法(MET)是促进远端输尿管结石患者结石排出的一种合适选择。本荟萃分析旨在比较坦索罗辛、西洛多辛和他达拉非单药治疗及联合治疗对结石排出率(SER)和结石排出时间(SET)的疗效和安全性,以及它们的相对安全性、绞痛发作次数和镇痛需求。
通过检索截至2023年11月27日的PubMed、Scopus和Web of Science获取随机对照试验。还在谷歌学术中进行手工检索以查找其他记录。纳入了比较上述至少两种药物在成人远端输尿管结石≤10 mm患者中的安全性和疗效的英文论文。
总共确定了27项研究(6项通过数据库检索,21项通过检查参考文献列表和在谷歌学术中手工检索)。其中超过一半(=15项,56%)在印度进行。与坦索罗辛相比,西洛多辛使SER显著提高(优势比[OR]2.24,<0.001),而SET的差异不显著。与坦索罗辛相比,他达拉非的SER显著更高(OR 1.42,=0.042),SET无差异。对5毫克和10毫克剂量他达拉非的亚组分析显示,SER或SET无显著差异。我们发现他达拉非和坦索罗辛在镇痛需求(平均差[MD -53.73,=0.2])或绞痛发作平均次数(MD -0.42,=0.060)方面无显著差异。西洛多辛和他达拉非之间的SER或SET无显著差异。与坦索罗辛相比,他达拉非加坦索罗辛导致更高的SER(OR 1.87,<0.001)和SET(MD -2.99,=0.002),不良反应无显著差异。
与坦索罗辛相比,西洛多辛、他达拉非以及他达拉非加坦索罗辛联合治疗使SER显著提高。同时,仅他达拉非加坦索罗辛与坦索罗辛之间的SET差异显著。似乎他达拉非和西洛多辛在SET和SER方面疗效相似。所有药物排石疗法的安全性相当。